ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1765

Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis

Malin Erlandsson 1, Karin Andersson 1, Nisha Nair 2, Anastasius Damdimopoulos 3, Sofia Silfverswärd 1, Rille Pullerits 1, Anne Barton 2 and Maria Bokarewa1, 1Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, 2Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, 3Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: CD4 cells and IL-9, interferon, Rheumatoid arthritis (RA), survivin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M088: Cytokines & Cell Trafficking (1764–1769)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage, and disability. This is often explained by a diversity of molecular processes in the early and established phases of RA. The purpose of this study was to assess cytokine-dependent change in DNA methylation in CD4+ T cells of patients with early and established RA.

Methods: A cross-sectional RA cohort was analysed by comparing patients with the disease duration < 3y (mean 1.7y, n=23), 3-10y (mean 5.6y, n=94) and >10y (mean 19y, n=68). Serum levels of cytokines were measured by ELISA. Genome-wide DNA methylation was performed in sorted and activated CD4+ T cells of early (mean 1.3y, n=10) and established (mean 12.6y, n=14) RA patients using Infinium MethylationEPIC BeadChip (Illumina). Chromatin was immunoprecipitated with survivin (BIRC5) of CD4+T cells and coupled with high throughput sequencing (Hiseq2000, Illumina). False discovery rate was calculated using the Benjamini method.

Results: The groups differed with respect to the serum levels of IFNg, IL9, and IL6. The patients with RA< 3y had low cytokine levels and high serum survivin, while the patients with RA >10y had high IFN, IL9, and BIRC5 mRNA, suggesting IFNg and IL9 to be important for maintaining disease activity in patients with the established RA. The differential DNA methylation in CD4+ T cells of early and established RA (p< 10-5) identified IFNg- and IL9-dependent change in CpG rich areas. In dominating majority of CpG areas, an increase of cytokines was associated with a reduction of DNA methylation, which is known to precede the initiation of gene transcription. Since patients with established RA frequently combined high cytokines with high BIRC, we analyzed if this affects DNA methylation. Comparing CD4 with high and low BIRC5, we found that 85% of IFNg-dependent and 67% of IL9-dependent DNA methylation changes occurred in presence of high BIRC5. To study if BIRC5 is found attached to chromatin, we performed chromatin immunoprecipitation in CD4+T cells. Analysis of the BIRC5-bound chromatin revealed enrichment for IRF-specific sequences where IRF1- and IRF8-binding sequences, but not IRF3 and IRF2 were predominantly found. We also found enrichment with complex sequences specific for binding bZIP-IRF (and not IRF-bZIP) and IRF-BATF sequences.

Conclusion: IFNg and IL9 are important for maintaining disease activity in patients with the established RA. In collaboration with intracellular survivin (BIRC5), these cytokines change the DNA methylation and gene transcription in CD4+ cells.


Disclosure: M. Erlandsson, None; K. Andersson, None; N. Nair, None; A. Damdimopoulos, None; S. Silfverswärd, None; R. Pullerits, None; A. Barton, None; M. Bokarewa, None.

To cite this abstract in AMA style:

Erlandsson M, Andersson K, Nair N, Damdimopoulos A, Silfverswärd S, Pullerits R, Barton A, Bokarewa M. Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/interferon-gamma-supports-transcriptional-activity-of-birc5-in-cd4-t-cells-in-established-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-gamma-supports-transcriptional-activity-of-birc5-in-cd4-t-cells-in-established-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology